Who owns Ginkgo Bioworks?

Who owns Ginkgo Bioworks?

Ginkgo Bioworks founders Jason Kelly, Reshma Shetty, Barry Canton, Austin Che and Tom Knight with [+] Some 400 employees of synthetic biology company Ginkgo Bioworks traveled to New York City to celebrate the company’s start of trading today on the New York Stock Exchange.

Who is the CEO of Ginkgo Bioworks?

CEO Jason Kelly
Ginkgo Bioworks CEO Jason Kelly on the business of programmable DNA.

What is ginkgo company?

Ginkgo Bioworks is an analytics company that designs microorganisms for customers in a range of industries. It is the self-proclaimed “Organism Company” and is one of the world’s largest privately held biotech companies. As of 2019, it was valued at $4.2 billion.

Is Ginkgo Bioworks profitable?

SEC documents show that the company pulled in $77 million in revenue in 2020, which increased to about $88 million in the first six months of 2021 (per an August investor call). The company has also reported losses: including $126.6 million in December 2020 and $119.3 million in 2019.

Who is Ginkgo Bioworks merging with?

Soaring Eagle Acquisition
Ginkgo Bioworks to Go Public With $1.63B in Proceeds From SPAC Merger. NEW YORK – Ginkgo Bioworks said on Tuesday that it has completed its merger with special purpose acquisition company Soaring Eagle Acquisition and that its stock will start to trade publicly on the New York Stock Exchange on Friday.

Is Ginkgo Bioworks a publicly traded company?

Ginkgo Bioworks — a Boston-based company that wants to make biology as easy to program as a computer — began trading on Friday after going public via a SPAC. Why it matters: Ginkgo’s multibillion-dollar offering is a milestone in the maturation of synthetic biology from a science to a true industry.

When was Ginkgo Bioworks founded?

2009
Ginkgo Bioworks/Founded

Is ginkgo a public company?

Is ginkgo synthetic biology story?

Is Ginkgo’s synthetic-biology story worth $15 billion? The Boston genetic engineering company Ginkgo Bioworks and its CEO, Jason Kelly, have been spectacularly successful selling a story: that synthetic biology will transform the manufacture of physical products. The point is that biology can make just about anything.

Is Zymergen publicly traded?

Zymergen raised $500 million when it went public in April, on top of more than $1 billion in venture funding.

What is DNA WS stock?

Warrant (DNA.WS) Real-Time Quotes | Nasdaq….DNA.WS Real-Time Quotes.

NLS Volume	0
Previous Close
Today’s High / Low	/
52 Week High / Low	$4.5/$1.58